Anti-Vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Report

Anti-Vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Beovu), By Disease (Diabetic Retinopathy, AMD), By Region (APAC, North America), And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-4-68038-346-1
  • Number of Pages: 105
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation and Scope
                        1.1.1 Segment Scope
                        1.1.2 Regional Scope
                        1.1.3 Estimates And Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                        1.3.1 Purchased Database:
                        1.3.2 Gvr’s Internal Database
                        1.3.3 Secondary Sources
                        1.3.4 Primary Research
                        1.3.5 Details Of Primary Research
                   1.4 Information or Data Analysis
                        1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                        1.6.1 Commodity Flow Analysis
                   1.7 List of Secondary Sources
                   1.8 List of Abbreviations
                   1.9 Objectives
                        1.9.1 Objective 1
                        1.9.2 Objective 2
                        1.9.3 Objective 3
                        1.9.4 Objective 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
Chapter 3 Anti-VEGF Therapeutics Market Variables, Trends, & Scope
                   3.1 Market Lineage Outlook
                        3.1.1 Parent Market Outlook
                        3.1.2 Ancillary Market Outlook
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Regulatory and Reimbursement Scenario
                   3.4 Market Dynamics
                        3.4.1 Market Driver Analysis
                        3.4.2 Market Restraint Analysis
                   3.5 Anti-VEGF Therapeutics: Market Analysis Tools
                        3.5.1 Industry Analysis - Porter’s
                        3.5.2 Pestel Analysis
                   3.6 Pipeline Analysis
                        3.6.1 Pipeline Analysis, By Phase
Chapter 4 Anti-VEGF Therapeutics Market: Segment Analysis, By Disease, 2017 - 2028 (USD Million)
                   4.1 Anti-VEGF Therapeutics Market: Disease Movement Analysis
                   4.2 Market Size & Forecasts and Trend Analyses, 2017 to 2028
                   4.3 Macular Edema
                        4.3.1 Macular Edema Market, 2017 - 2028 (USD Million)
                   4.4 Diabetic Retinopathy
                        4.4.1 Diabetic Retinopathy Market, 2017 - 2028 (USD Million)
                   4.5 Retinal Vein Occlusion
                        4.5.1 Retinal Vein Occlusion Market, 2017 - 2028 (USD Million)
                   4.6 Age-related Macular Degeneration
                        4.6.1 Age-Related Macular Degeneration Market, 2017 - 2028 (USD Million)
Chapter 5 Anti-VEGF Therapeutics Market: Segment Analysis, By Product, 2017 - 2028 (USD Million)
                   5.1 Anti-VEGF Therapeutics Market: Product Movement Analysis
                   5.2 Market Size & Forecasts and Trend Analyses, 2017 to 2028
                   5.3 Eylea
                        5.3.1 Eylea Market Estimates And Forecast, 2017 - 2028 (USD Million)
                   5.4 Lucentis
                        5.4.1 Lucentis Market Estimates And Forecast, 2017-2028, (USD Million)
                   5.5 Beovu
                        5.5.1 Beovu Market Estimates And Forecast, 2017-2028, (USD Million)
Chapter 6 Anti-VEGF Therapeutics Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)
                   6.1 Anti-VEGF Therapeutics Market: Regional Movement Analysis
                   6.2 Regional Market Share Analysis, 2020 & 2028
                   6.3 Regional Market Snapshot
                   6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2017 to 2028
                        6.4.1 North America
                            6.4.1.1 North America market estimates and forecast, 2017-2028 (USD Million)
                            6.4.1.2 U.S.
                                6.4.1.2.1 U.S. anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.1.3 Canada
                                6.4.1.3.1 Canada anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                        6.4.2 Europe
                            6.4.2.1 Europe anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.2.2 U.K.
                                6.4.2.2.1 U.K. anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.2.3 Germany
                                6.4.2.3.1 Germany anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.2.4 Spain
                                6.4.2.4.1 Spain anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.2.5 France
                                6.4.2.5.1 France anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.2.6 Italy
                                6.4.2.6.1 Italy anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                        6.4.3 Asia Pacific
                            6.4.3.1 Asia Pacific anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.3.2 Japan
                                6.4.3.2.1 Japan anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.3.3 China
                                6.4.3.3.1 China anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.3.4 India
                                6.4.3.4.1 India anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.3.5 Australia
                                6.4.3.5.1 Australia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                        6.4.4 Latin America
                            6.4.4.1 Latin America anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.4.2 Brazil
                                6.4.4.2.1 Brazil anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.4.3 Mexico
                                6.4.4.3.1 Mexico anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.4.4 Argentina
                                6.4.4.4.1 Argentina anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                        6.4.5 MEA
                            6.4.5.1 MEA anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.5.2 South Africa
                                6.4.5.2.1 South Africa anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.5.3 Saudi Arabia
                                6.4.5.3.1 Saudi Arabia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
                            6.4.5.4 UAE
                                6.4.5.4.1 UAE anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Chapter 7 Anti-VEGF Therapeutics Market: Competitive Analysis
                   7.1 Recent Developments & Impact Analysis, by Key Market Participants
                        7.1.1 New Product Launch
                        7.1.2 Mergers & Acquisitions
                        7.1.3 Licensing And Partnerships
                   7.2 Company Categorization
                        7.2.1 Innovators
                        7.2.2 Market Leaders
                        7.2.3 Heat Map Analysis
                   7.3 Vendor Landscape
                        7.3.1 List Of Key Distributors And Channel Partners
                        7.3.2 Key Customers
                        7.3.3 Key Company Market Share Analysis, 2020
                   7.4 Public Companies
                        7.4.1 Company Market Position Analysis
                        7.4.2 Company Market Position Analysis
                        7.4.3 Competitive Dashboard Analysis
                   7.5 Private Companies
                        7.5.1 List Of Key Emerging Companies
                   7.6 Company Profiles
                        7.6.1 F. HOFFMANN-LA ROCHE LTD
                        7.6.2 BAYER AG
                        7.6.3 REGENERON PHARMACEUTICALS INC.
                        7.6.4 NOVARTIS AG
                        7.6.5 BIOGEN
                        7.6.6 COHERUS BIOSCIENCES
                        7.6.7 PFIZER INC.
                        7.6.8 VIATRIS INC. (MYLAN N.V)
                        7.6.9 AMGEN INC.


List of Tables

TABLE 1 List of abbreviation
TABLE 2 North America anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 3 North America anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 4 U.S. anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 5 U.S. anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 6 Canada anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 7 Canada anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 8 Europe anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 9 Europe anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 10 U.K. anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 11 U.K. anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 12 Germany anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 13 Germany anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 14 France anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 15 France anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 16 Italy anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 17 Italy anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 18 Spain anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 19 Spain anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 20 Asia Pacific anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 21 Asia Pacific anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 22 Japan anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 23 Japan anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 24 China anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 25 China anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 26 India anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 27 India anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 28 Australia anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 29 Australia anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 30 Latin America anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 31 Latin America anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 32 Brazil anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 33 Brazil anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 34 Mexico anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 35 Mexico anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 36 Argentina anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 37 Argentina anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 38 MEA anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 39 MEA anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 40 South Africa anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 41 South Africa anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 42 Saudi Arabia anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 43 Saudi Arabia anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
TABLE 44 UAE anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
TABLE 45 UAE anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)


List of Figures

FIG. 1 Anti-VEGF therapeutics market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Market outlook (2020)
FIG. 10 Segment Outlook (Type, 2020)
FIG. 11 Penetration & growth prospect mapping
FIG. 12 Market driver relevance analysis (Current & future impact)
FIG. 13 Geriatric population in 2019 and 2050
FIG. 14 Market restraint relevance analysis (Current & future impact)
FIG. 15 Porter’s five forces analysis
FIG. 16 PESTEL analysis
FIG. 17 Anti-VEGF therapeutics market disease type outlook: Key takeaways
FIG. 18 Anti-VEGF therapeutics market: Disease type movement analysis
FIG. 19 Macular edema market, 2017 - 2028 (USD Million)
FIG. 20 Diabetic retinopathy market, 2017 - 2028 (USD Million)
FIG. 21 Retinal vein occlusion market, 2017 - 2028 (USD Million)
FIG. 22 Age-related macular degeneration market, 2017 - 2028 (USD Million)
FIG. 23 Anti-VEGF therapeutics market product outlook: Key takeaways
FIG. 24 Anti-VEGF therapeutics market: Product movement analysis
FIG. 25 Eylea market, 2017 - 2028 (USD Million)
FIG. 26 Macular edema market, 2017 - 2028 (USD Million)
FIG. 27 Diabetic retinopathy market, 2017 - 2028 (USD Million)
FIG. 28 Retinal vein occlusion market, 2017 - 2028 (USD Million)
FIG. 29 Age-related macular degeneration market, 2017 - 2028 (USD Million)
FIG. 30 Lucentis estimates and forecast, 2017-2028 (USD Million)
FIG. 31 Macular edema market, 2017 - 2028 (USD Million)
FIG. 32 Diabetic retinopathy market, 2017 - 2028 (USD Million)
FIG. 33 Retinal vein occlusion market, 2017 - 2028 (USD Million)
FIG. 34 Age-related macular degeneration market, 2017 - 2028 (USD Million)
FIG. 35 Beovu estimates and forecast, 2017 - 2028 (USD Million)
FIG. 36 Regional outlook, 2020 & 2028
FIG. 37 Regional market place: Key takeaways
FIG. 38 North America
FIG. 39 North America anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 40 U.S.
FIG. 41 U.S. anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 42 Canada
FIG. 43 Canada anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 44 Europe
FIG. 45 Europe anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 46 UK
FIG. 47 UK anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 48 Germany
FIG. 49 Germany anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 50 Spain
FIG. 51 Spain anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 52 France
FIG. 53 France anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 54 Italy
FIG. 55 Italy anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 56 Asia Pacific
FIG. 57 Asia Pacific anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 58 Japan
FIG. 59 Japan anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 60 China
FIG. 61 China anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 62 India
FIG. 63 India anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 64 Australia
FIG. 65 Australia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 66 Latin America
FIG. 67 Latin America anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 68 Brazil
FIG. 69 Brazil anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 70 Mexico
FIG. 71 Mexico anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 72 Argentina
FIG. 73 Argentina anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 74 Middle East and Africa
FIG. 75 MEA anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 76 South Africa
FIG. 77 South Africa anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 78 Saudi Arabia
FIG. 79 Saudi Arabia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 80 UAE
FIG. 81 UAE anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
FIG. 82 Strategy mapping
FIG. 83 Heat map analysis
FIG. 84 Company market share analysis, 2020
FIG. 85 Company market position analysis
FIG. 86 Company market position analysis
FIG. 87 Market differentiators

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon